NCT05035706Active, not recruitingEarly phase 1
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
Source: ClinicalTrials.gov · Last updated 22 Sept 2026
Brief summary (registry, in English)
This clinical trial assesses how the immune system responds to leukemia tumors after low dose radiation delivered as part of standard of care. The information learned in this study may help them know if adding immunotherapy (a type of treatment that uses the immune system to fight cancer) can be helpful in future leukemia patients receiving radiation.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- First submitted
- 25 Aug 2021
- Start date
- 30 Jun 2021
- Primary completion date
- 30 Apr 2028
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT05035706
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 10
- From 30 Jun 2021 to the primary completion date, 30 Apr 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients unwilling to undergo the biopsy before or after radiotherapy
Other
- Patients who are unwilling to participate
Who the study is looking for
- Patients diagnosed with new or recurrent myeloid leukemia
- Aged \>= 18 years old
- Eastern Cooperative Oncology Group (ECOG) performance status \< 4
- Patient have measurable and amenable to biopsy under local anesthesia without the need for imaging directed procedure
- Ability to understand and provide signed informed consent
- Females must be surgically or biologically sterile or postmenopausal (amenorrhoeic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment. Women of childbearing potential must agree to use an adequate method of contraception during the study and until the last radiation treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study and until the last radiation treatment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.